6-(p-vinylbenzamido)hexanoic acid | 184433-62-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-(p-vinylbenzamido)hexanoic acid
• 英文别名: 6-(p-Vinylbenzamido)-1-hexanoic acid；6-[(4-ethenylbenzoyl)amino]hexanoic acid
• CAS: 184433-62-3
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: YUQRMBDNBJNPHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-乙烯基苯甲酸 在 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 120.0h， 生成 6-(p-vinylbenzamido)hexanoic acid
  参考文献：
  名称：

  Conjugation of Arg-Gly-Asp (RGD) Sequence in Copolymer Bearing Sugar Moiety for Insulinoma Cell Line (MIN6) Culture

  摘要：

  为胰岛素瘤细胞（MIN6）培养合成了由粘附分子的Arg-Gly-Asp（RGD）序列和糖分子组成的共聚物。与其他聚合物涂层表面相比，附着在聚(N-对乙烯基苄基-D-丙二酰胺-co-6-(对乙烯基苯甲酰胺)-己酸-g-GRGDS)（p(VMA-co-VBGRGDS)）涂层平皿上的 MIN6 细胞更易聚集。与 p（VLA-co-VBGRGDS）相比，p（VMA-co-VBGRGDS）也显示 MIN6 细胞的增殖速度更快（高出约 18%）。通过细胞与基质之间的相互作用，与未受刺激的细胞相比，p(VMA-co-VBGRGDS) 产生的 MIN6 细胞胰岛素分泌量高出约 80%，而 poly(N-p-vinylbenzyl-D-lactonamide-co-6-(p-vinylbenzamido)-hexanoic acid-g-GRGDS) （p(VLA-co-VBGRGDS）产生的胰岛素分泌量高出约 50%。此外，用 RGD 单体处理的 MIN6 细胞的附着在 p（VMA-co-VBGRGDS）表面被抑制了约 50%。这一结果支持了一种观点，即 p（VMA-co-VBGRGDS）共聚物中 RGD 肽的粘附分子与 MIN6 细胞膜上的整合素家族发生了特异性相互作用。

  DOI：

  10.1271/bbb.65.1284

文献信息

• MICROPARTICLES OF ALGINATE MODIFIED WITH RGD AS A RELEASE SYSTEM FOR MEDICINES
  申请人：Universidad del Pais Vasco

  公开号：EP2174656A1

  公开（公告）日：2010-04-14

  The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the microcapsule with a peptide which can bind to the adhesion proteins of the cell membrane, such that the cells act as cross-linking agents of the matrix resulting in an improvement of the mechanical properties of the matrixes

  本发明的目的是提供含有细胞的聚合材料颗粒，其中所述颗粒的强度大大高于现有技术中已知的微胶囊。本发明的目的是提供一种含有细胞的聚合材料颗粒，其中所述颗粒的强度大大高于现有技术中已知的微胶囊的强度。实现所述强度的方法是将形成微胶囊的聚合材料功能化，使其含有一种能与细胞膜粘附蛋白结合的肽，从而使细胞成为基质的交联剂，从而改善基质的机械性能。
• METHODS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Traslational Cancer Drugs Pharma, S.L.

  公开号：EP2316970A2

  公开（公告）日：2011-05-04

  The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKp expression levels.

  本发明涉及基于诱导胆碱激酶β（以下简称ChoKβ）活性治疗癌症的方法，以及设计个性化疗法和确定能够诱导胆碱激酶β（以下简称ChoKβ）的药物对治疗癌症的反应的方法，还涉及基于确定ChoKβ表达水平以及基于确定ChoKβ和ChoKα表达水平之间的关系确定患者预后的方法。最后，本发明涉及根据PEMT和/或ChoKp表达水平的测定来确定癌症患者对ChoKα抑制剂的反应的方法。
• USE OF MICROPARTICLES CONTAINING GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Universidad del Pais Vasco

  公开号：EP2322147A1

  公开（公告）日：2011-05-18

  The present invention relates to methods for the treatment of neurodegenerative diseases by means of the use of microparticles comprising genetically modified cells expressing neurotrophic and/or angiogenic factors and wherein said microparticles are administered by means of implantation at the cerebral cortex level.

  本发明涉及通过使用包含表达神经营养因子和/或血管生成因子的转基因细胞的微颗粒治疗神经退行性疾病的方法，其中所述微颗粒通过在大脑皮层水平植入的方式给药。
• RGD-MODIFIED ALGINATE MICROPARTICLES AS A DRUG RELEASE SYSTEM
  申请人：Orive Arroyo Gorka

  公开号：US20100272812A1

  公开（公告）日：2010-10-28

  The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the microcapsule with a peptide which can bind to the adhesion proteins of the cell membrane, such that the cells act as cross-linking agents of the matrix resulting in an improvement of the mechanical properties of the matrixes
• METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Lacal Sanjuan Juan Carlos

  公开号：US20110250179A1

  公开（公告）日：2011-10-13

  The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels.